159 related articles for article (PubMed ID: 30546143)
41. Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.
Ning SF; Li JL; Luo CP; Wei CH; Lu YK; Liu HZ; Wei WE; Zhang LT
Int J Clin Exp Pathol; 2014; 7(12):8740-7. PubMed ID: 25674240
[TBL] [Abstract][Full Text] [Related]
42. HER2 testing in breast carcinoma: very low concordance rate between reference and local laboratories in Brazil.
Wludarski SC; Lopes LF; Berto E Silva TR; Carvalho FM; Weiss LM; Bacchi CE
Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):112-8. PubMed ID: 20930616
[TBL] [Abstract][Full Text] [Related]
43. Modulatory effect of neoadjuvant chemotherapy on the prognosis of patients with breast cancer.
Trifunovic J; Memisevic N; Nikolin B; Salma S; Dugandzija T; Vidovic V
J BUON; 2017; 22(2):638-643. PubMed ID: 28730768
[TBL] [Abstract][Full Text] [Related]
44. Development of an evidence-based approach to external quality assurance for breast cancer hormone receptor immunohistochemistry: comparison of reference values.
Makretsov N; Gilks CB; Alaghehbandan R; Garratt J; Quenneville L; Mercer J; Palavdzic D; Torlakovic EE; ;
Arch Pathol Lab Med; 2011 Jul; 135(7):874-81. PubMed ID: 21732777
[TBL] [Abstract][Full Text] [Related]
45. Prognostic significance of estrogen receptor, progesterone receptor, HER2/neu, Ki-67, and nm23 expression in patients with invasive breast cancer.
Cubukcu E; Kanat O; Fatih Olmez O; Kabul S; Canhoroz M; Avci N; Deligonul A; Hartavi M; Cubukcu S; Olmez F; Kurt E; Evrensel T; Gokgoz S; Manavoglu O
J BUON; 2013; 18(2):359-65. PubMed ID: 23818346
[TBL] [Abstract][Full Text] [Related]
46. Could the Breast Prognostic Biomarker Status Change During Disease Progression? An Immunohistochemical Comparison between Primary Tumors and Synchronous Nodal Metastasis.
El Nemr Esmail RS; El Farouk Abdel-Salam LO; Abd El Ellah MM
Asian Pac J Cancer Prev; 2015; 16(10):4317-21. PubMed ID: 26028092
[TBL] [Abstract][Full Text] [Related]
47. Institutional quality assurance for breast cancer HER2 immunohistochemical testing: identification of outlier results and impact of simultaneous fluorescence in situ hybridization cotesting.
Green IF; Zynger DL
Hum Pathol; 2015 Dec; 46(12):1842-9. PubMed ID: 26412217
[TBL] [Abstract][Full Text] [Related]
48. [Morphological features of basal-like subtype invasive carcinoma of breast].
Gao LX; Yang GZ; Ding HY; Li L
Zhonghua Bing Li Xue Za Zhi; 2008 Feb; 37(2):83-7. PubMed ID: 18681317
[TBL] [Abstract][Full Text] [Related]
49. Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence.
Bogina G; Lunardi G; Coati F; Zamboni G; Gori S; Bortesi L; Marconi M; Cassandrini PA; Turazza M; Cortesi L; DeMatteis E; Ficarra G; Ibrahim T; Serra P; Medri L; Giraudi S; Lambertini M; Carli F; Foglietta J; Sidoni A; Nunzi M; Ficorella C; Diadema MR; Del Mastro L
Tumori; 2015; 101(4):398-403. PubMed ID: 26045108
[TBL] [Abstract][Full Text] [Related]
50. Alterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosis.
Ba JL; Liu CG; Jin F
Asian Pac J Cancer Prev; 2014; 15(21):9233-9. PubMed ID: 25422206
[TBL] [Abstract][Full Text] [Related]
51. Lessons Learned, Challenges Taken, and Actions Made for "Precision" Immunohistochemistry. Analysis and Perspectives From the NordiQC Proficiency Testing Program.
Nielsen S; Bzorek M; Vyberg M; Røge R
Appl Immunohistochem Mol Morphol; 2023 Aug; 31(7):452-458. PubMed ID: 36194495
[TBL] [Abstract][Full Text] [Related]
52. Differential cellular localization of CELSR2 and ING4 and correlations with hormone receptor status in breast cancer.
Jiang L; Zhang X; Xiang C; Geradts J; Wei Q; Liang Y; Huang H; Xu JF
Histol Histopathol; 2018 Aug; 33(8):835-842. PubMed ID: 29489009
[TBL] [Abstract][Full Text] [Related]
53. Impact of host and histopathological factors on the discrepancies in estrogen receptor, and progesterone receptor, and HER2 status between core needle biopsy and surgically excised tumors.
Nakamura R; Yamamoto N; Shiina N; Miyaki T; Ikebe D; Itami M; Shida T; Miyazaki M
Breast; 2016 Apr; 26():141-7. PubMed ID: 26732051
[TBL] [Abstract][Full Text] [Related]
54. Tissue microarray (TMA) versus whole section immunohistochemistry in the assessment of ER/PR and Her-2/neu status in a breast cancer series from Sudan.
Awadelkarim KD; Arizzi C; Elamin EO; Osman I; Mekki SO; Biunno I; Barberis MC; Mariani-Costantini R
Breast J; 2013; 19(4):446-7. PubMed ID: 23721068
[No Abstract] [Full Text] [Related]
55. [Interlaboratory trials for quality assurance of breast cancer biomarkers in Germany].
Krusche CA; von Wasielewski R; Rüschoff J; Fisseler-Eckhoff A; Kreipe HH
Pathologe; 2008 Jul; 29(4):315-20. PubMed ID: 18504581
[TBL] [Abstract][Full Text] [Related]
56. Allelic imbalance at the HER2/TOP2A locus in breast cancer.
Huijsmans CJ; van den Brule AJ; Rigter H; Poodt J; van der Linden JC; Savelkoul PH; Hilbink M; Hermans MH
Diagn Pathol; 2015 May; 10():56. PubMed ID: 26022247
[TBL] [Abstract][Full Text] [Related]
57. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
[TBL] [Abstract][Full Text] [Related]
58. Academic and nonacademic laboratories perform equally on CIQC immunohistochemistry proficiency testing.
Chen ZW; Neufeld H; Copete MA; Garratt J; Gilks CB; Torlakovic EE
Am J Clin Pathol; 2013 Jul; 140(1):55-60. PubMed ID: 23765534
[TBL] [Abstract][Full Text] [Related]
59. Association between immunohistochemical expression of topoisomerase IIalpha, HER2 and hormone receptors and response to primary chemotherapy in breast cancer.
Manna Edel F; Teixeira LC; Alvarenga M
Tumori; 2006; 92(3):222-9. PubMed ID: 16869240
[TBL] [Abstract][Full Text] [Related]
60. Biological markers of invasive breast cancer.
Matsumoto A; Jinno H; Ando T; Fujii T; Nakamura T; Saito J; Takahashi M; Hayashida T; Kitagawa Y
Jpn J Clin Oncol; 2016 Feb; 46(2):99-105. PubMed ID: 26486826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
